Ignite Creation Date:
2024-05-06 @ 7:53 AM
Last Modification Date:
2024-10-26 @ 11:54 AM
Study NCT ID:
NCT02628886
Status:
UNKNOWN
Last Update Posted:
2020-10-23
First Post:
2015-12-07
Brief Title:
Protecting From Pneumococcus in Early Life The PROPEL Trial
Sponsor:
London School of Hygiene and Tropical Medicine
Organization:
London School of Hygiene and Tropical Medicine
Study Overview
Official Title:
A Randomized Controlled Double-blind Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROPEL
Brief Summary:
Streptococcus pneumoniae is responsible for over 10 percent of death in children under five and many of these deaths occur in early infancy before the current pneumococcal schedule is effective and nearly half occur in sub Saharan Africa
The PROPEL trial will examine the effect of either a maternal or a neonatal dose of a pneumococcal conjugate vaccine on pneumococcal colonisation in the nose which can be used to measure the risk of disease in early life
600 Expectant mothers will be randomized at between 28 and 34 weeks to a maternal group a neonatal group or a control group in equal number 200 per group Their subsequent born offspring will be followed up until nine months of age Infants born from expectant mothers in the maternal and control group will receive their subsequent pneumococcal conjugate vaccination according to the national Expanded Programme on Immunisation EPI schedule in the Gambia at 8 12 and 16 weeks while infants born to expectant mothers in the control group will receive the pneumococcal conjugate vaccine within 48 hours of birth and at 8 and 16 weeks of life Randomization will be undertaken by defined un-blinded members of the clinical trial team who will be delegated for this task and who will not be involved in any other trial related procedures Pregnant women who are willing and who are identified by the staff of the government antenatal clinic as being potentially eligible according to gestation assessed initially according to the date of the last menstrual period LMP - if known or the fundal height will be referred to a member of the clinical trial team
Those who remain interested in participation having had the details of the study explained will have basic demographic obstetric and contact details collected and will be invited at a time of their convenience to the Medical Research Council MRC clinical trial site for the formal informed consent process to be completed Following informed consent pregnancy will be confirmed with a urinary pregnancy test Initial screening eg for past-obstetric history and past-medical history etc will be undertaken at this point along with screening bloods for serology HIV hepatitis B and syphilis and haematology haemoglobin and sickle test A dating ultrasound scan USS will also be undertaken by designated clinical trial staff On completion of screening expectant mothers who are confirmed to be eligible according to the defined inclusion and exclusion criteria will be enrolled and randomized in parallel into one of three equally sized groups mentioned above maternal neonatal control
According to the group into which they have been randomized mothers will receive a dose of PCV13 and tetanus toxoid maternal group placebo 09 sodium chloride and tetanus toxoid control group or tetanus toxoid alone neonatal group From this point on the maternal and control groups now Routine EPI Schedule will be followed up in exactly the same way for the purposes of interventions and all endpoint assessments Infants in the neonatal group Neonatal Schedule will be followed up according to the schedule outlined
At the time of presentation to the delivery unit a blood sample for serology and malaria Rapid Diagnostic Test RDT and an nasopharyngeal swab NPS sample will be obtained prior to or shortly following delivery Immediately following delivery a sample of cord blood will be obtained and as soon as possible an NPS sample will be taken from the newborn Anthropometric measurements will be taken from the newborn and an examination conducted Once there has not been any contraindication to vaccination identified all newborns will be administered the routine EPI vaccines according to the schedule in The Gambia BCG Hepatitis B and OPV Those newborns in the Neonatal group will additionally be administered a single intramuscular IM dose of PCV13 At two three and four months infants will be administered the routine EPI vaccines Those infants in the Maternal and Control Groups Routine EPI Schedule will additionally receive PCV13 at eight 12 and 16 weeks while those in the Neonatal group will receive the vaccine at eight and 16 weeks only having received the first dose at birth All infants will additionally receive a single dose of the inactivated poliovirus vaccine IPV at 16 weeks in line with the routine EPI schedule in The Gambia
Following the vaccines administered to expectant mothers and following the vaccines administered at birth home visits will be undertaken on day 1 to 6 to collect solicited local and systemic adverse for PCV only reactions and any unsolicited A day 7 safety clinic visit will be conducted following the vaccines administered to expectant mothers and following the vaccines administered at birth Infant will attend the clinical trial site for NPS and blood samples to be taken at specific time points
The PROPEL trial will examine the effect of either a maternal or a neonatal dose of a pneumococcal conjugate vaccine on pneumococcal colonisation in the nose which can be used to measure the risk of disease in early life
600 Expectant mothers will be randomized at between 28 and 34 weeks to a maternal group a neonatal group or a control group in equal number 200 per group Their subsequent born offspring will be followed up until nine months of age Infants born from expectant mothers in the maternal and control group will receive their subsequent pneumococcal conjugate vaccination according to the national Expanded Programme on Immunisation EPI schedule in the Gambia at 8 12 and 16 weeks while infants born to expectant mothers in the control group will receive the pneumococcal conjugate vaccine within 48 hours of birth and at 8 and 16 weeks of life Randomization will be undertaken by defined un-blinded members of the clinical trial team who will be delegated for this task and who will not be involved in any other trial related procedures Pregnant women who are willing and who are identified by the staff of the government antenatal clinic as being potentially eligible according to gestation assessed initially according to the date of the last menstrual period LMP - if known or the fundal height will be referred to a member of the clinical trial team
Those who remain interested in participation having had the details of the study explained will have basic demographic obstetric and contact details collected and will be invited at a time of their convenience to the Medical Research Council MRC clinical trial site for the formal informed consent process to be completed Following informed consent pregnancy will be confirmed with a urinary pregnancy test Initial screening eg for past-obstetric history and past-medical history etc will be undertaken at this point along with screening bloods for serology HIV hepatitis B and syphilis and haematology haemoglobin and sickle test A dating ultrasound scan USS will also be undertaken by designated clinical trial staff On completion of screening expectant mothers who are confirmed to be eligible according to the defined inclusion and exclusion criteria will be enrolled and randomized in parallel into one of three equally sized groups mentioned above maternal neonatal control
According to the group into which they have been randomized mothers will receive a dose of PCV13 and tetanus toxoid maternal group placebo 09 sodium chloride and tetanus toxoid control group or tetanus toxoid alone neonatal group From this point on the maternal and control groups now Routine EPI Schedule will be followed up in exactly the same way for the purposes of interventions and all endpoint assessments Infants in the neonatal group Neonatal Schedule will be followed up according to the schedule outlined
At the time of presentation to the delivery unit a blood sample for serology and malaria Rapid Diagnostic Test RDT and an nasopharyngeal swab NPS sample will be obtained prior to or shortly following delivery Immediately following delivery a sample of cord blood will be obtained and as soon as possible an NPS sample will be taken from the newborn Anthropometric measurements will be taken from the newborn and an examination conducted Once there has not been any contraindication to vaccination identified all newborns will be administered the routine EPI vaccines according to the schedule in The Gambia BCG Hepatitis B and OPV Those newborns in the Neonatal group will additionally be administered a single intramuscular IM dose of PCV13 At two three and four months infants will be administered the routine EPI vaccines Those infants in the Maternal and Control Groups Routine EPI Schedule will additionally receive PCV13 at eight 12 and 16 weeks while those in the Neonatal group will receive the vaccine at eight and 16 weeks only having received the first dose at birth All infants will additionally receive a single dose of the inactivated poliovirus vaccine IPV at 16 weeks in line with the routine EPI schedule in The Gambia
Following the vaccines administered to expectant mothers and following the vaccines administered at birth home visits will be undertaken on day 1 to 6 to collect solicited local and systemic adverse for PCV only reactions and any unsolicited A day 7 safety clinic visit will be conducted following the vaccines administered to expectant mothers and following the vaccines administered at birth Infant will attend the clinical trial site for NPS and blood samples to be taken at specific time points
Detailed Description:
Members of the clinical trial team will base themselves within the government run antenatal clinics at the clinical trial sites in order to identify potentially eligible pregnant women Working closely alongside government midwifery and nursing staff they will aim to identify pregnant women who are yet to reach 34 weeks gestation and who are thus potentially eligible for enrolment Assessment of gestation at this first contact point will be based on the date of the LMP or the assessment of fundal height as is local practice gestational age will be confirmed by ultrasound scanning once informed consent has been obtained and ultrasound based assessment will be used to determine final eligibility
A member of the clinical trial team will discuss the study with potentially eligible expectant mothers who are provisionally interested and agree to receive this additional information The discussion will be based on the contents of the informed consent document ICD and a copy of the ICD will be provided to the expectant mother at the end of the discussion
Potentially eligible women who are interested will be encouraged to discuss the study with their spouse and other family members as appropriate Following individual sensitization of the mother a member of the field team may provide information to other family members particularly the spouse either by telephone or through a visit to the subjects residence according to the preference of the mother
Expectant mothers who express an interest in participation will then be contacted to arrange a visit to the clinical trial site where informed consent will be undertaken Writtenthumb-printed informed consent will only be required from the expectant mother but in all cases it will be confirmed directly with the spouse the father of the unborn baby that they are aware of the study and have given their agreement In the case of expectant mothers who are literate in English they will be provided with a copy of the ICD but a member of the clinical trial team will nonetheless review the contents of the ICD line by line in English to ensure all details are covered and that the subject has the opportunity to ask questions regarding any aspect of the trial
In the case of potential participants who are not literate in English but only in one of the local languages a member of the clinical trial team fluent in the local language as well as being English literate will review the ICD line by line translating directly from the English ICD to the appropriate local language In this case an impartial witness must be present throughout all elements of the consent process and must attest that the information on the ICD has been given accurately and in full The impartial witness will also be required to sign the ICD to confirm that this has been the case
Informed consent for study participation will be documented on the signature page of the ICD The option to consent for the future use of any residual samples on study completion will also be given on the same page but the provision of such additional consent is not required for participation in the main trial
A certified copy of the ICD is provided to the participant unless it is refused for some reason in which case it will be filed at the trial site Such refusal must be documented in the subjects file so it is clear that the subject has been offered a copy The study will randomize 600 pregnant women at between 28 and 34 weeks gestation Mothers will not be replaced following randomization Screening of potentially eligible women will continue until this number is reached unless the trial is stopped for some other reason
No further selection or assessment of eligibility will be undertaken on the newborn infants All data will be included in the safety reporting irrespective of pregnancy outcome and safety follow-up should occur as planned for all infants An infant may be excluded from the trial for the purposes of vaccination andor clinical sampling if ongoing participation is considered to be against their best interests or if a contraindication to vaccination andor to the obtaining of clinical samples is identified An infant excluded in this way would not be replaced and hence this would not alter the target sample size of 600 pregnant women
A member of the clinical trial team will discuss the study with potentially eligible expectant mothers who are provisionally interested and agree to receive this additional information The discussion will be based on the contents of the informed consent document ICD and a copy of the ICD will be provided to the expectant mother at the end of the discussion
Potentially eligible women who are interested will be encouraged to discuss the study with their spouse and other family members as appropriate Following individual sensitization of the mother a member of the field team may provide information to other family members particularly the spouse either by telephone or through a visit to the subjects residence according to the preference of the mother
Expectant mothers who express an interest in participation will then be contacted to arrange a visit to the clinical trial site where informed consent will be undertaken Writtenthumb-printed informed consent will only be required from the expectant mother but in all cases it will be confirmed directly with the spouse the father of the unborn baby that they are aware of the study and have given their agreement In the case of expectant mothers who are literate in English they will be provided with a copy of the ICD but a member of the clinical trial team will nonetheless review the contents of the ICD line by line in English to ensure all details are covered and that the subject has the opportunity to ask questions regarding any aspect of the trial
In the case of potential participants who are not literate in English but only in one of the local languages a member of the clinical trial team fluent in the local language as well as being English literate will review the ICD line by line translating directly from the English ICD to the appropriate local language In this case an impartial witness must be present throughout all elements of the consent process and must attest that the information on the ICD has been given accurately and in full The impartial witness will also be required to sign the ICD to confirm that this has been the case
Informed consent for study participation will be documented on the signature page of the ICD The option to consent for the future use of any residual samples on study completion will also be given on the same page but the provision of such additional consent is not required for participation in the main trial
A certified copy of the ICD is provided to the participant unless it is refused for some reason in which case it will be filed at the trial site Such refusal must be documented in the subjects file so it is clear that the subject has been offered a copy The study will randomize 600 pregnant women at between 28 and 34 weeks gestation Mothers will not be replaced following randomization Screening of potentially eligible women will continue until this number is reached unless the trial is stopped for some other reason
No further selection or assessment of eligibility will be undertaken on the newborn infants All data will be included in the safety reporting irrespective of pregnancy outcome and safety follow-up should occur as planned for all infants An infant may be excluded from the trial for the purposes of vaccination andor clinical sampling if ongoing participation is considered to be against their best interests or if a contraindication to vaccination andor to the obtaining of clinical samples is identified An infant excluded in this way would not be replaced and hence this would not alter the target sample size of 600 pregnant women
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None